[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626792":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":43,"collaborators":24,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":24,"enrollmentInfo":55,"targetDuration":24,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":69,"whyStopped":24,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental group","EXPERIMENTAL","Prednisone 60 mg\u002Fday for 7 days.",[13],"Drug: oral prednisone or placebo at a dose of 60 mg per day for 7 days",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","PLACEBO_COMPARATOR","Placebo of prednisone 60 mg\u002Fday for 7 days.",[13],[20],{"type":21,"name":22,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","oral prednisone or placebo at a dose of 60 mg per day for 7 days",[15,9],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Benjamin ROSSI, PhD","CONTACT","+33 1 45 21 37 58","benjamin.rossi@ght-gpne.fr",[32],{"facility":33,"status":24,"city":34,"state":24,"zip":24,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":24},"Hopital Robert Ballanger","Aulnay-sous-Bois","France","FR",{"type":38,"coordinates":39},"Point",[40,41],2.49402,48.93814,{"lat":41,"lon":40},{"type":44,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100626792","phase-2-evaluation-of-the-efficacy-of-corticosteroids-in-septic-arthritis-in-adults-100626792",false,"NCT07440238","Evaluation of the Efficacy of Corticosteroids in Septic Arthritis in Adults","Evaluation of the Efficacy of Corticosteroids in Septic Arthritis in Adults: Randomized Double-blind Controlled Trial","CORSAR","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Documented septic arthritis (microorganism identified intra-articularly by culture or PCR, or by turbid synovial fluid with positive Gram stain, or positive blood cultures)\n* Effective antibiotic therapy initiated within ≤ 3 days\n* Effective contraception for women of childbearing age during treatment period\n* Signed informed consent\n* Affiliation to the French national health insurance system\n* Ability to read, write, and understand French\n\nExclusion Criteria:\n\n* Polyarticular septic arthritis (≥ 2 joints)\n* Septic arthritis of small joints (e.g., fingers: proximal interphalangeal joint (PIP), distal interphalangeal joints (DIP), MetaCarpoPhalangeal (MCP); toes: MTP)\n* Systemic sclerosis\n* Pyomyositis\n* Diabetic foot infection\n* Current corticosteroid therapy for another indication\n* Inability to take oral medication\n* Contraindication to corticosteroids\n* Associated endocarditis\n* Presence of prosthetic joint or osteosynthesis material in the affected joint\n* Septic shock\n* Severe soft tissue wound overlying the joint\n* Aplastic chemotherapy\n* Neutropenia (defined as neutrophils \\\u003C 500\u002Fmm³)\n* Mycobacterial infection\n* Fungal infection\n* Sickle cell disease\n* Current pregnancy\n* Breastfeeding women\n* Patients under legal protection (e.g., guardianship)\n* Participation in another interventional clinical trial\n* Uncontrolled diabetes\n* Unstable psychiatric disorders\n* Adults unable to provide informed consent\n* Contraindication to corticosteroid therapy","ALL","18 Years",{"count":56,"type":57},200,"ESTIMATED","INTERVENTIONAL",[60],"PHASE2","Septic arthritis is a severe infection associated with significant morbidity and mortality. Despite eradication of the microorganisms, persistent inflammation may lead to substantial long-term functional joint sequelae. The use of corticosteroids could reduce this inflammation, thereby improving functional joint outcomes and facilitating first-line medical treatment. The hypothesis of this study is that corticosteroid administration, in addition to antibiotic therapy, reduces persistent inflammation and improves functional joint prognosis in adult patients with acute septic arthritis.",[63],"Septic Arthritis",[65,66,67,68],"Articular prognosis","Corticosteroid","Acute septic arthritis","Antibiotic therapy","NOT_YET_RECRUITING","2026-02-26",{"date":72,"type":73},"2026-02-27","ACTUAL",{"date":75,"type":57},"2026-03-30",{"date":77,"type":57},"2026-09",{"name":5,"class":6},1]